

[Open Peer Review on Qeios](#)

Milatumumab-Doxorubicin Antibody-Drug Conjugate IMMU-110

National Cancer Institute

Source

National Cancer Institute. *Milatumumab-Doxorubicin Antibody-Drug Conjugate IMMU-110*. NCI Thesaurus. Code C91086.

An immunoconjugate consisting of milatumumab, a humanized monoclonal antibody against CD74, conjugated to the anthracycline antibiotic doxorubicin with potential antineoplastic activity. The milatumumab moiety of this ADC selectively binds to CD74 on tumor cell surfaces; upon internalization, the doxorubicin moiety is released, where it intercalates between base pairs in the DNA helix and inhibits topoisomerase II, thereby preventing DNA replication and increasing double-strand breakage. As a result, this agent may inhibit the proliferation of cancer cells that overexpress CD74. CD74, an integral membrane protein and tumor associated antigen (TAA), is overexpressed in certain cancer cells and promotes survival in rapidly proliferating tumor cells.